Printer Friendly

BRITISH BIO-TECHNOLOGY AND SMITHKLINE BEECHAM SIGN AGREEMENT FOR RESEARCH COLLABORATION

 BRITISH BIO-TECHNOLOGY AND SMITHKLINE BEECHAM
 SIGN AGREEMENT FOR RESEARCH COLLABORATION
 PHILADELPHIA, April 30 /PRNewswire/ -- British Bio-technology Group plc and SmithKline Beecham (NYSE: SBH) announced that they have signed an agreement for the collaborative research and commercialization of a class of compounds which may be useful as new treatments for arthritis and cancer.
 Under the agreement, the companies will pursue joint research, coordinated development and marketing of matrix metalloproteinase inhibitors (MMPIs) which are pharmaceutical agents useful in preventing damage to matrix tissue such as occurs in arthritis and certain cancers, and have been extensively researched by both companies.
 Each company will fund its own research and development program. British Bio-technology will develop anti-invasive cancer therapies arising from the collaborative research, and have exclusive worldwide marketing rights. SmithKline Beecham will develop disease-modifying anti-arthritic therapies arising from the research, and have exclusive marketing rights in the United States and Japan and co-marketing rights in Europe with British Bio-technology.
 Dr. Keith McCullagh, British Bio-technology's chief executive officer, said: "We have pursued research successfully in previous collaborations with SmithKline Beecham. Our respective scientists have confidence in each other's abilities. This new collaboration extends our relationship and establishes the basis for reciprocal product development."
 Dr. George Poste, SmithKline Beecham's chairman of Research and Development, said: "We have a major commitment to research in diseases involving inflammation and tissue repair, particularly in arthritis. The collaboration with British Bio-technology will provide a significant increase of resources to an extremely complex disease, enhancing the chances of achieving success."
 British Bio-technology's first MMPI compound, BB-94, for the treatment of invasive cancer was synthesized under a research collaboration with SmithKline Beecham. British Bio-technology has exclusive worldwide commercial rights for this product. BB-94 has completed initial toxicological testing and is expected to begin clinical trials shortly.
 British Bio-technology is an emerging pharmaceutical company, founded in 1986, which is currently pursuing research and development in inflammation and inflammatory diseases such as asthma and arthritis; cancer, particularly tumor invasion and spread; vascular diseases such as thrombosis and myocardial infarction; and immunotherapy of viral disease, particularly AIDS. British Bio-technology now has one pharmaceutical product in clinical trials and two more that are scheduled to commence clinical trials in mid-1992. The company is based in Oxford, England.
 SmithKline Beecham, one of the world's leading healthcare companies, markets prescription and consumer medicines, animal health products and clinical laboratories services. In addition to inflammation and tissue repair, SmithKline Beecham's research focuses on cardiopulmonary disease, anti-infectives, central nervous system disorders, and gastrointestinal disorders. The company is based in London with U.S. headquarters in Philadelphia.
 /delval/
 -0- 4/30/92
 /CONTACT: Katie Arber, 011-44-865-748747, or Anne McBride, 212-688-1036, both of British Bio-technology, or Alan Chandler, 011-44-81-975-2290, or Sharyn Arnold, 215-751-7074, both of SmithKline Beecham/
 (SBH) CO: SmithKline Beecham; British Bio-technology Group plc ST: Pennsylvania IN: MTC SU: JVN


MP -- PH009 -- 4806 04/30/92 10:01 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1992
Words:478
Previous Article:SUN MEDICAL CO. OFFERS UNIQUE REFERRAL SERVICE TO HOME PATIENTS THROUGH PHARMACIES
Next Article:MERRIMAC ACQUIRES MRD (MICROWAVE RESEARCH & DEVELOPMENT)


Related Articles
MICHIGAN DEPARTMENT OF PUBLIC HEALTH AND SMITHKLINE BEECHAM ANNOUNCE VACCINE COLLABORATION
CORIXA ANNOUNCES INFECTIOUS DISEASE RESEARCH AND DEVELOPMENT COLLABORATION WITH SB
SMITHKLINE BEECHAM ENTERS RESEARCH COLLABORATIONS IN CHINA; NEXT STEP IN EXPANDING PRESENCE IN CHINESE HEALTHCARE
NPS Announces Extension Of Osteoporosis Agreement With SmithKline Beecham
Cadus and SmithKline Beecham Sign Research Collaboration With Potential Funding to Cadus of $68 Million
Corixa Corporation Establishes Cancer Vaccine Research Collaboration and License Agreement With SmithKline Beecham Biologicals
Corixa and SmithKline Beecham Biologicals Extend Tuberculosis Collaboration
Corixa Reports Third Quarter Results.
Prolifaron, SmithKline Beecham Team Up.
ArQule Announces Drug Discovery Collaboration with SmithKline Beecham.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters